This non-systematic review identified recent clinical and epidemiological studies identified from PubMed/Medline and ClinicalTrials.gov from the US NIH and the Cochrane Register of Controlled Trials using the search terms bronchiectasis, non-cystic fibrosis bronchiectasis, chronic pulmonary infection and computed tomography. Case reports, editorials and other communications with a low evidence level were excluded.
Summary
Aims: Non-cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterised by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production and recurrent pulmonary infections. In the last several decades, its prevalence has increased, making it likely to be encountered in the primary care setting. The aim was to review the clinical presentation and diagnosis of NCFB, with an emphasis on the role of computed tomography (CT).
Methods: For this review, trials and reports were identified from PubMed/Medline and ClinicalTrials.gov from the US NIH and the Cochrane Register of Controlled Trials.
The search used keywords: bronchiectasis, non-cystic fibrosis bronchiectasis, chronic pulmonary infection and computed tomography. No date/language restrictions were used.
Results: Non-cystic fibrosis bronchiectasis often coexists with other respiratory conditions, such as chronic obstructive pulmonary disease. The prevalence of NCFB is increasing, particularly in women and older individuals, possibly as a result of increased physician awareness and widespread use of CT, which is the gold standard for the diagnosis of NCFB. CT can assist in identifying an underlying cause of NCFB and determining the extent and severity of the disease.
Discussion:
Non-cystic fibrosis bronchiectasis should be suspected in the primary care setting in patients with chronic cough, purulent sputum and frequent respiratory infections that tend to resolve slowly or partially. Early diagnosis and determination of the extent and severity of the disease by CT and other tests are critical to establish therapy to improve quality of life and potentially slow progressive decline of lung function in patients with NCFB.
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| INTRODUCTION
Bronchiectasis is a chronic, progressive respiratory disorder characterised by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production and recurrent pulmonary infections. 1 The changes in the bronchial walls may be due to chronic inflammation secondary to recurrent or chronic infections in the lung, but often the exact cause is not identified.
1 Symptoms vary from intermittent episodes of respiratory infections with excessive mucus production to chronic symptoms with persistent daily expectoration of purulent sputum. 1 In patients without cystic fibrosis, the condition is known as non-cystic fibrosis bronchiectasis (NCFB). [1] [2] [3] Although NCFB was once a very uncommon diagnosis, in the last two decades its prevalence has been increasing, making it more likely that primary care clinicians will encounter these patients in their practice. The precise prevalence of NCFB is difficult to determine because estimates vary among populations, but studies report a prevalence ranging from 486 to 1106
per 100 000 persons with an incidence that appears to be rising, particularly in women and older individuals. [4] [5] [6] Although not as common as asthma, which affects approximately 10% of the world population, NCFB has become far more common than other respiratory conditions such as idiopathic pulmonary fibrosis, which affects only 18.2 per 100 000 persons. 7, 8 Hospitalisation rates owing to NCFB have also increased in the United States, particularly in the older population. Non-cystic fibrosis bronchiectasis is associated with comorbidities such as anxiety, depression, fatigue, and has a significant impact on quality of life. 10 Patients with NCFB require longer hospital stays and more outpatient visits compared with matched controls. 4 Cough associated with NCFB can also impact the quality of life of family members.
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The effect of NCFB on mortality is not clear. Although reported mortality rates vary, evidence suggests that age-adjusted mortality rates in patients with NCFB are at least twice that of the general population.
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The increased recognition of NCFB is likely a result of the use of high-resolution computed tomography (HRCT), which has allowed for the identification of previously undiagnosed disease. [11] [12] [13] HRCT, which is able to acquire 1-mm thick images of the lung at 10-mm intervals, is considered the gold standard for radiographic diagnosis of NCFB. 1,2 Other modalities of CT using different imaging algorithms have been frequently used to effectively diagnose bronchiectasis. 12, 14 With enhanced diagnostic capabilities of CT for NCFB, it is important for primary care clinicians to have an understanding of the information that can be obtained with this procedure. Herein, we review key radiographic findings on CT in the context of an overview of the pathophysiology, clinical presentation, and the diagnosis of NCFB.
| METHODS
For this review, trials and reports were identified from the databases of PubMed/Medline and ClinicalTrials.gov from the US NIH and the Cochrane Register of Controlled Trials. The search was carried out using the keywords or combinations of keywords: bronchiectasis, non-cystic fibrosis bronchiectasis, chronic pulmonary infection and computed tomography. The term chronic pulmonary infection was included to capture the articles that discussed this condition in association with CT as a possible precursor of the development of NCFB.
A particular emphasis was made on publications that discussed the epidemiology, natural history, clinical presentation and diagnosis. In addition, there was a focus on the available studies and publications that examined the role of CT in the diagnosis of bronchiectasis and determination of severity. No date or language restrictions were used.
| PATHOPHYSIOLOGY OF NCFB
Cole's 'vicious cycle' of infection, airway inflammation and lung damage 15 is the most widely accepted mechanism of the development of NCFB (Figure 1 ). The cycle is triggered when the defence system of the lung is breached and mucociliary clearance is impaired. 
| The Association Between COPD and Bronchiectasis
Chronic obstructive pulmonary disease (COPD) remains one of the most common pulmonary conditions worldwide, and patients with COPD are often seen in the primary care setting. 21 Bronchiectasis and COPD often coexist with a varying prevalence amongst study populations (29%-57%). T A B L E 1 Conditions associated with the development of bronchiectasis 1, 14 patients with bronchiectasis and COPD had an increased risk of allcause mortality. 26 A meta-analysis of 881 patients, including the above studies in addition to four others, revealed that the coexistence of COPD and bronchiectasis was associated with higher exacerbation rates, degree of inflammatory markers, and rates of Pseudomonas aeruginosa isolation. 27 For these reasons, bronchiectasis is now considered a common comorbidity in patients with COPD. 21 However, it is incompletely understood how these diseases exactly influence each other.
The leading theory is that increased colonisation of the airways leads to increased inflammation, which in turn translates into increased risk for exacerbations. 28 Future studies are needed to understand this complex association and to evaluate if identification of these patients early in their course may change outcomes.
| CLINICAL PRESENTATION
Non-cystic fibrosis bronchiectasis presents with a range of clinical manifestations from incidentally found bronchiectasis in asymptomatic individuals to massive haemoptysis and respiratory failure.
With the widespread use of CT, clinicians increasingly encounter the 'incidental' finding of bronchiectasis in asymptomatic patients who undergo chest or abdominal imaging for unrelated purposes. However, the most common clinical presentation is between these extremes.
For those patients with symptomatic bronchiectasis, the most common complaint is chronic cough. In fact, many patients have a chronic productive cough for over 30 years before their diagnosis. In one study of 103 adults with NCFB, 98% reported a chronic cough, while daily sputum production (typically purulent and averaging greater than 30 mL in volume) occurred in 76% of patients. 29 Dyspnoea (62%) and chronic fatigue (74%) are also common presenting symptoms. 29, 30 Other common characteristics in these patients include chronic rhinosinusitis that ranges from intermittent nasal discharge to severe purulent sinusitis (present in 70% of patients) and a notable history of ear, nose and throat surgery for recurrent sinusitis (30% of patients).
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Mild, intermittent haemoptysis occurs in 26%-51% of cases, but at times it can be severe and life-threatening. 29, 31 Many patients with bronchiectasis require frequent hospital admissions for recurrent pneumonia. 29, 31 Depression and anxiety are common in patients with bronchiectasis, which may significantly affect their quality of life. 32, 33 The natural history of NCFB is punctuated by periods of exacerbations, defined as acute worsening of respiratory symptoms that require management with antibiotic therapy. 34 Patients with exacerbations experience change in one or more of the common symptoms of bronchiectasis, including increased sputum production or purulence, worsening cough and dyspnoea, and systemic symptoms. 1 Usually, these episodes are triggered by a bronchial infection. In a study of 115 patients with NCFB, the most common signs of an acute exacerbation were increased frequency of cough (88%) and change in sputum characteristics (67%). 35 Other symptoms included fever (28%), increase in sputum volume (42%) and increase in sputum purulence (35%). 35 Exacerbations can range from a mild increase in respiratory symptoms to life-threatening haemoptysis and respiratory failure. When should bronchiectasis be suspected in the primary care setting?
The diagnosis should be suspected in patients with chronic cough (ie, >6 weeks) with variable production of purulent sputum, with or without recurrent haemoptysis, and frequent respiratory infections that tend to resolve slowly or partially with or without an underlying condition such as COPD. In some instances, bronchiectasis may be suggested on chest radiographs. This constellation of signs and symptoms should prompt the primary care provider to consider evaluating the patient for bronchiectasis.
| DIAGNOSTIC APPROACH

| Initial investigations
Physical exam and history may contribute to the diagnosis of bronchiectasis. The most common respiratory physical exam findings are crackles, occurring in up to 73% of patients. 29, 31 Other common findings include rhonchi (44%) and wheezing (21%-34%). 29, 31 Clubbing of the digits is rare and occurs in 2%-3% of cases. 
| Computed tomography
High-resolution computed tomography of the chest is the current gold standard for the diagnosis/confirmation of bronchiectasis. It has a sensitivity of 96% and a specificity of 93%. 13 Nevertheless, HRCT has some limitations, including respiratory and cardiac pulsation artefacts, falsenegative reports due to missed focal areas of bronchiectasis between section-planes, and misinterpretation of bronchial-artery ratio measurements. 11 These limitations have been partially addressed using alternative CT modalities using different imaging algorithms. For example, a retrospective study evaluated the efficacy of HRCTs with 1-mm slices every 10 mm, compared with multi-detector CTs (MDCT) with contiguous 1-mm slices for the diagnosis of bronchiectasis. 12 MDCT was found to be superior in assessing the presence, extent and severity of bronchiectasis compared with HRCT. 12 These findings were further supported by a prospective study, showing that MDCT indeed had greater accuracy for the identification and exclusion of bronchiectasis compared with HRCT.
14 Although the utility of MDCT appears to be equivalent or even superior to HRCT, the radiation dose is up to five times higher with MDCT. 38 Because of this concern, the use of low-dose volumetric CT has been explored for the diagnosis of bronchiectasis. One such study by Jung and colleagues demonstrated no significant difference in the diagnostic yield of bronchiectasis, showing similar image quality and radiation exposures compared with HRCT. 39 Despite these advances, regular volumetric CT is sufficient to make the diagnosis of NCFB. This imaging modality offers the same degree of accuracy for NCFB and may be more widely available.
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As imaging technology progresses, it is likely that newer tools will be developed to better assess the presence and severity of bronchiectasis. The development of automated image analysis is one exciting innovation that has the potential to advance this diagnostic area, making it easier to identify milder forms of the disease and to improve the reliability of the diagnosis. 41, 42 By diagnosing patients with bronchiectasis earlier in their course, it would allow for earlier therapeutic intervention, with the potential to improve outcomes and alter the course of the disease.
The characteristic feature of NCFB demonstrated by CT is bronchial wall dilation with the luminal diameter greater than 1-1.5 the size of the accompanying pulmonary artery branch. Other typical findings include absence of normal tapering of the bronchi, bronchial wall thickening, mucoid plugging of the airways and proximity of visible airways close to the pleura (<1 cm). 1, 43 Bronchiectasis is classified by morphology. In cylindrical bronchiectasis, the bronchial walls are dilated, but maintain their cylindrical shape extending to the periphery of the lung (Figure 2A Certain infections also may have a characteristic presentation. For example, atypical mycobacteria may favour the right middle lobe and the lingula. 45 Despite identification of these key features on CT and extensive testing, no underlying aetiology is found in a large proportion of patients with bronchiectasis. 46 The prevalence of idiopathic bronchiectasis varies amongst cohorts (32%-66%) likely owing to geographic variations, diagnostic algorithms and other determinants. 30, [47] [48] [49] [50] [51] Clinical symptoms, history of exacerbations and microbiological data are frequently used to stratify the severity of patients with NCFB;
however, the incorporation of imaging abnormalities into these classifications may allow for a more complete picture of the impact of the disease. 52, 53 Therefore, there is great interest in the evaluation of the extent and severity of bronchiectasis more objectively using CT.
A method to quantify the extent of the disease using CT was developed several decades ago. 54 In this method, each lobe is scored 
| Pulmonary function testing
Spirometry is frequently used to evaluate patients with respiratory symptoms. In bronchiectasis, the majority of patients present with mild to moderate airway obstruction, with a forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio less than 70, along with an FEV1 >50% predicted. 29, 31 Significant bronchodilator response (response of >200 mL and 12% predicted in FEV1
and FVC after administration of β 2 agonists 57 ) occurs in only 22%
of patients with NCFB. 29 Interestingly, patients with a significant bronchodilator response tend to have more severe obstruction and poorer lung function as recently reported by Guan and colleagues.
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More severe obstruction (ie, FEV1<50% predicted) is also associated with a history of pseudomonas infection or colonisation, multilobar involvement of disease, greater sputum volume, greater purulent sputum and those patients with at least four exacerbations over a 2-year period. 58 It is important to note that spirometry may not significantly differ between the stable and exacerbation states. 35 Although one study showed a statistically significant decline of both FEV1 and FVC by 3% (P≤.01) between the stable and exacerbation states, this is unlikely to be clinically significant. 59 Spirometry should be performed at least annually in patients with bronchiectasis to detect progression of the disease. 1 Pulmonary function testing may help detect and determine the severity of other underlying conditions such as interstitial lung disease, asthma and pulmonary hypertension.
| Microbiology
Sputum cultures should be obtained in all patients with bronchiectasis. The most common organisms initially isolated from the sputum of patients with NCFB are Gram-negative bacteria including
Haemophilus influenzae (47%), P. aeruginosa (12%) and Moraxella catarrhalis (8%). 60 Over time, this microbiological distribution shifts slightly, with Pseudomonas increasing in frequency. Six years after diagnosis, the most commonly isolated organisms continue to be H. influenzae (40%), P. aeruginosa (18%) and M. catarrhalis (7%). 60 Gram-positive bacteria are rare. Streptococcus pneumoniae is isolated in 4% of samples and Staphylococcus aureus is found in 3% of samples. 60 Isolation of P. aeruginosa is particularly important clinically. Patients with Pseudomonas have more severe disease, more rapid decline in lung function, more frequent exacerbations and reduced quality of life. [60] [61] [62] [63] Thus, these patients need to be followed more carefully and referred to a pulmonologist for consideration of more aggressive therapeutic options. 61 Non-tuberculous mycobacteria (NTM) constitute another group of important microorganisms in patients with NCFB and account for 2%-30% of pathogens isolated. [64] [65] [66] [67] In patients with bronchiectasis, the incidence of lung infection with NTM has increased over the past decades. [68] [69] [70] The most common NTM isolated in NCFB is Mycobacaterium avium complex. [65] [66] [67] The diagnosis of NTM is particularly challenging in patients with NCFB because of existing abnormalities that may or may not be caused by NTM.
Unlike Mycobaterium tuberculosis, NTM are harboured in the soil and water, and infection is acquired from these sources rather 
| Laboratory investigations
Once bronchiectasis is suspected based on clinical presentation and confirmed by radiographic imaging, determining the underlying cause is a key to effective therapeutic management. Initial laboratory tests should always include sputum culture, gram stain and three acid-fast bacterial stains with culture to evaluate and treat an acute infectious process that may be ongoing. 1 Microbiologic testing should be repeated in the patient presenting with worsening symptoms.
There is no consensus on how often microbiologic testing should be performed in the "stable" patient, but experts advocate testing the sputum for pathogenic bacteria from every visit to every 6 months. 
| When should primary care consult a specialist?
Because bronchiectasis may be associated with progressive lung function decline and recurrent pulmonary infections, it is important for this disease to be recognised early so appropriate interventions can be instituted. The first step is to attempt to identify underlying causes of bronchiectasis (as discussed above and shown in Figure 3) and treat them when indicated. In the primary care setting, patients with bronchiectasis should be followed periodically for an assess- 
| CONCLUSION
The incidence of NCFB has risen over the past decades. The reasons for this increase is multifactorial and may be related to improved physician awareness, improved testing and widespread availability of CT.
Other, more complex, explanations such as the rise in the incidence of infections, antibiotic resistance and increased incidence of autoimmune conditions likely play a part in the increased rate in which NCFB is encountered in clinical practice. The conditions associated with the development of NCFB are varied and the diagnostic workup should target these when clinically indicated. In the primary care setting, it is important to consider the diagnosis of bronchiectasis in patients with chronic respiratory symptoms that cannot be explained by another diagnosis. CT of the chest is the gold standard for the diagnosis of NCFB. In addition, this tool provides a wealth of information that may be used to identify an underlying condition and determine the extent and severity of the disease. With early and improved diagnosis of NCFB, it is more likely that therapeutic regimens will be effective and prevent the progression of the disease.
